S-1: INVO Fertility Registers 9.4M Shares for Armistice Resale

INVO Fertility, Inc. files an S-1 registration statement for the resale of up to 9.4 million common shares by Armistice Capital, stemming from a recent warrant inducement agreement.

Summary

• INVO Fertility, Inc. (IVF) has filed an S-1 registration statement for the resale of up to 9,467,456 shares of common stock by Armistice Capital Master Fund Ltd.
• These shares are issuable upon the exercise of an Inducement Warrant, which was granted to Armistice Capital on January 28, 2026, with an exercise price of $1.59 per share.
• The Inducement Warrant was issued in consideration for Armistice Capital exercising existing warrants for cash at a reduced price of $1.59 per share, which generated approximately $7,500,000 in gross proceeds for the company.
• The company will not receive proceeds from the *resale* of these shares but expects to receive up to $15,053,255 if Armistice Capital fully exercises the Inducement Warrant.
• INVO Fertility is a healthcare services and technology company focused on the fertility market, operating INVO Centers and IVF clinics, and distributing its INVOcell medical device.
• The company recently divested 80.1% of NAYA Therapeutics, Inc. in May 2025 to refocus exclusively on fertility.
• Maxim Group LLC is acting as the exclusive lead warrant solicitation agent for the exercise of the Existing Warrants, receiving a 6.5% fee on the gross proceeds (approximately $487,500) and up to $20,000 for expenses.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative. While the potential for capital inflow from warrant exercise is positive, the significant potential for dilution from the resale of shares by a major stockholder and the 'going concern' warning from auditors temper enthusiasm.

Positives

• The company expects to receive up to $15,053,255 in gross proceeds upon the exercise of the Inducement Warrant, which can be used for acquisitions of additional fertility clinics, capital expenditures, and working capital.
• The acquisition of Wisconsin Fertility Institute (WFI) in August 2023 more than tripled annual revenue and became a significant source of positive cash flow, accelerating the company's expansion into healthcare services.
• The INVOcell device and IVC procedure offer a lower-cost, more accessible fertility treatment option with comparable success rates to traditional IVF.
• The company's strategy to build and acquire fertility clinics, including INVO Centers, aims to expand access to assisted reproductive technology (ART) care and increase revenue per fertility cycle.

Negatives

• The registration of 9,467,456 shares for resale by Armistice Capital represents a significant potential for dilution to existing stockholders.
• The sale of a substantial number of shares by the Selling Stockholder could cause the trading price of the common stock to decline.
• The company has a history of issuing shares and warrants, and converting convertible notes, which has led to ongoing dilution.
• The audit report for the fiscal year ended December 31, 2024, included an explanatory paragraph regarding the company's ability to continue as a going concern.

Risks

• The Selling Stockholder may choose to sell the shares at prices below the current market price, which could adversely affect the market price of the company's Common Stock.
• The issuance of Common Stock to the Selling Stockholder upon exercise of the Inducement Warrant may cause substantial dilution to existing stockholders.
• The sale of a substantial number of shares of Common Stock by the Selling Stockholder, or the anticipation of such sales, could cause the trading price of the Common Stock to decline or make it more difficult for the company to sell equity or equity-related securities in the future.
• Management will have broad discretion over the use of net proceeds received upon exercise of the Inducement Warrant, and these proceeds may not be invested successfully or improve operating results.
• Investing in the company's securities is highly speculative and involves a high degree of risk.
• The company's ability to continue as a going concern is a risk factor, as noted in the audit report for December 31, 2024.

Future Outlook

The company intends to use potential proceeds from warrant exercises primarily for acquisitions of additional fertility clinics and related businesses, capital expenditures, working capital, and general and administrative expenses, indicating a strategy of continued expansion in the fertility market. The company also plans to seek out additional innovative fertility-focused technologies to license or acquire.

Management Comments

• "Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics, including INVO Centers dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by our INVOcell medical device (INVOcell) and US-based, in vitro fertilization (IVF) clinics."
• "The acquisition accelerated our expansion from a medical device company to a healthcare services company and immediately added scale and a significant source of positive cash flow to our operations." (Referring to the Wisconsin Fertility Institute acquisition)
• "We believe dedicated INVO Centers require less investment than traditional IVF clinics and are operationally efficient, making them ideal for underserved secondary markets."
• "We plan on opening additional wholly owned INVO Centers in the coming years."
• "We believe the IVC procedure can deliver comparable results at a lower cost than traditional IVF and is a significantly more effective treatment than intrauterine insemination (IUI)."
• "While INVOcell remains part of our efforts, our commercial and corporate development strategy within the fertility market has expanded to focus more broadly on providing ART services through our emphasis on operating clinics."

Industry Context

StockSavvy.ai notes that INVO Fertility's strategy to expand access to assisted reproductive technology (ART) through a hybrid model of proprietary device sales (INVOcell) and clinic operations (INVO Centers and IVF clinics) positions it to capitalize on the growing demand for fertility treatments. The divestment of NAYA Therapeutics to refocus on fertility aligns with a trend towards specialization in healthcare, allowing for more concentrated resource allocation in a high-growth sector. The emphasis on lower-cost options like IVC could disrupt traditional IVF markets, particularly in underserved areas, by making treatments more accessible.

Comparison to Industry Standards

• The company's INVOcell device is presented as the world's first intravaginal culture technique, offering comparable pregnancy success and live birth rates to traditional IVF at a lower cost. This positions it as a potentially more affordable alternative to established IVF providers like Progyny or CooperSurgical's fertility solutions.
• The strategy of acquiring established and profitable IVF clinics, such as the Wisconsin Fertility Institute, which 'more than tripled our annual revenue' and provided 'a significant source of positive cash flow,' suggests a growth model similar to larger consolidators in the fertility space, aiming for scale and operational efficiency.
• The development of dedicated INVO Centers, which 'require less investment than traditional IVF clinics and are operationally efficient,' targets underserved secondary markets, potentially expanding the overall market for ART services beyond the reach of high-cost, urban-centric IVF chains.

Corporate Governance

Related Party Transactions

• Armistice Capital Master Fund Ltd. (the Selling Stockholder) has participated in multiple private placements and offerings with the company, including the December 2025 Offering, the August 2023 Offering, and the March 2023 Offering.
• Armistice Capital entered into an amendment to a securities purchase agreement (July 2023 SPA Amendment) where the company paid Armistice a $1,000,000 fee.
• The Inducement Letter Agreement, dated January 28, 2026, is a related party transaction with Armistice Capital, involving the exercise of existing warrants at a reduced price and the issuance of new inducement warrants.
• Maxim Group LLC, the financial advisor, received a 6.5% fee on gross proceeds from the exercise of Existing Warrants and reimbursement for expenses, and also acted as placement agent in the December 2025 private placement.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution due to the large number of shares registered for resale by Armistice Capital. The market price could decline if Armistice sells a substantial number of shares.
• **Investors (exercising warrants)**: Armistice Capital benefits from a reduced exercise price on existing warrants and the issuance of new inducement warrants, providing a favorable investment opportunity.
• **Company**: Benefits from potential capital inflow upon exercise of the Inducement Warrant, which can fund strategic growth initiatives like clinic acquisitions and technology development.
• **Employees/Management**: Management's discretion over the use of proceeds could impact future business direction and stability, potentially leading to growth opportunities.
• **Customers (fertility patients)**: The company's focus on expanding access to ART care, including lower-cost options like INVOcell, could benefit patients seeking fertility treatments by making them more accessible and affordable.

Next Steps

• The company will file a proxy statement on Schedule 14A after its Annual Report on Form 10-K for the period ended December 31, 2025, to seek Stockholder Approval for the issuance of shares underlying the Inducement Warrant.
• If Stockholder Approval is not obtained at the first meeting, the company will call a meeting every three months thereafter until approval is secured or the Inducement Warrant is no longer outstanding.
• The company will use commercially reasonable best efforts to cause the Resale Registration Statement to become effective within 60 calendar days (or 90 days in case of full SEC review) following the closing date of the Existing Warrants exercise.
• The company plans on opening additional wholly owned INVO Centers in the coming years.
• The company intends to seek out additional, innovative fertility-focused technologies to license or acquire.

Key Dates

Recommendation

While INVO Fertility's strategic focus on expanding fertility services and its proprietary INVOcell technology present long-term growth potential, the immediate impact of this S-1 filing is the significant potential for dilution from the resale of nearly 9.5 million shares by Armistice Capital. This, coupled with the auditor's 'going concern' warning, introduces considerable uncertainty and downward pressure on the stock price. The potential capital inflow from warrant exercise is positive, but the dilution risk warrants a cautious 'hold' stance until the market absorbs the new shares and the company demonstrates sustained financial improvement.

Keywords

fertility, INVOcell, IVF, assisted reproductive technology, ART, healthcare services, warrant, resale, dilution, Nasdaq, S-1, Armistice Capital, INVO Fertility